Translation of cell therapies into clinical practice requires the adoption of robust production protocols in order to optimize and standardize the manufacture and cryopreservation of cells, in compliance with good manufacturing practice regulations. Between 2012 and 2020, we conducted two phase I clinical trials (EudraCT 2009-014484-39, EudraCT 2015-004855-37) on amyotrophic lateral sclerosis secondary progressive multiple sclerosis patients, respectively, treating them with human neural stem cells. Our production process of a hNSC-based medicinal product is the first to use brain tissue samples extracted from fetuses that died in spontaneous abortion or miscarriage. It consists of selection, isolation and expansion of hNSCs and ends with the final pharmaceutical formulation tailored to a specific patient, in compliance with the approved clinical protocol. The cells used in these clinical trials were analyzed in order to confirm their microbiological safety; each batch was also tested to assess identity, potency and safety through morphological and functional assays. Preclinical, clinical and in vitro nonclinical data have proved that our cells are safe and stable, and that the production process can provide a high level of reproducibility of the cultures. Here, we describe the quality control strategy for the characterization of the hNSCs used in the above-mentioned clinical trials.

Profico, D., Gelati, M., Ferrari, D., Sgaravizzi, G., Ricciolini, C., Projetti Pensi, M., et al. (2022). Human Neural Stem Cell-Based Drug Product: Clinical and Nonclinical Characterization. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(21) [10.3390/ijms232113425].

Human Neural Stem Cell-Based Drug Product: Clinical and Nonclinical Characterization

Ferrari D.
;
Gelain F.;Vescovi A. L.
2022

Abstract

Translation of cell therapies into clinical practice requires the adoption of robust production protocols in order to optimize and standardize the manufacture and cryopreservation of cells, in compliance with good manufacturing practice regulations. Between 2012 and 2020, we conducted two phase I clinical trials (EudraCT 2009-014484-39, EudraCT 2015-004855-37) on amyotrophic lateral sclerosis secondary progressive multiple sclerosis patients, respectively, treating them with human neural stem cells. Our production process of a hNSC-based medicinal product is the first to use brain tissue samples extracted from fetuses that died in spontaneous abortion or miscarriage. It consists of selection, isolation and expansion of hNSCs and ends with the final pharmaceutical formulation tailored to a specific patient, in compliance with the approved clinical protocol. The cells used in these clinical trials were analyzed in order to confirm their microbiological safety; each batch was also tested to assess identity, potency and safety through morphological and functional assays. Preclinical, clinical and in vitro nonclinical data have proved that our cells are safe and stable, and that the production process can provide a high level of reproducibility of the cultures. Here, we describe the quality control strategy for the characterization of the hNSCs used in the above-mentioned clinical trials.
Articolo in rivista - Articolo scientifico
ATMP production; GMP; neural stem cells; quality control; standardization;
English
3-nov-2022
2022
23
21
13425
open
Profico, D., Gelati, M., Ferrari, D., Sgaravizzi, G., Ricciolini, C., Projetti Pensi, M., et al. (2022). Human Neural Stem Cell-Based Drug Product: Clinical and Nonclinical Characterization. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(21) [10.3390/ijms232113425].
File in questo prodotto:
File Dimensione Formato  
10281-397820_VoR.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 2.3 MB
Formato Adobe PDF
2.3 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/397820
Citazioni
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
Social impact